T. Rowe Price Associates
CLSD

T. Rowe Price Associates’s Clearside Biomedical CLSD Stock Holding History

T. Rowe Price Associates’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,547
Closed -$27K – 2940
2022
Q3 		$27K Hold
1,547
– – ﹤0.01% 2897
2022
Q2 		$34K Hold
1,547
– – ﹤0.01% 2900
2022
Q1 		$53K Buy
1,547
+754
+95% +$22.6K ﹤0.01% 2917
2021
Q4 		$33K Buy
+793
New +$51.4K ﹤0.01% 2947
2021
Q3 		– Sell
-2,480
Closed -$181K – 2947
2021
Q2 		$181K Sell
2,480
-827
-25% -$38.4K ﹤0.01% 2751
2021
Q1 		$123K Buy
+3,307
New +$166K ﹤0.01% 2766

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

T. Rowe Price Associates's CLSD Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Clearside Biomedical (CLSD) in Q4 2022, closing a stake of 1,547 shares — an estimated $27K sold.

T. Rowe Price Associates first reported a position in CLSD in Q1 2021 and held it in 6 quarters. The position peaked at $181K in Q2 2021. 53 funds tracked by Wall St. Rank hold CLSD as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Clearside Biomedical position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,547 Clearside Biomedical shares in Q4 2022, an estimated $27K.
  • T. Rowe Price Associates first reported a position in Clearside Biomedical in Q1 2021 and held it in 6 quarters.
  • T. Rowe Price Associates's Clearside Biomedical position peaked at $181K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.